4D Molecular Therapeutics Inc (NASDAQ: FDMT) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

4D Molecular Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $29.91 and fluctuated between $30.23 as its day high and $29.02 as its day low. The current market capitalization of 4D Molecular Therapeutics Inc is $1.48B. A total of 0.94 million shares were traded on the day, compared to an average of 1.02M shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, FDMT has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 6 SELLs from insiders. Insiders purchased 1,469,250 shares during that period but sold 616,995.

In the most recent transaction, Bizily Scott sold 1,750 shares of FDMT for 27.67 per share on Feb 16. After the transaction, the Chief Legal Officer now owns 1,737 company shares. In a previous transaction on Feb 08, Kirn David sold 92,001 shares at 27.13 per share. FDMT shares that Chief Executive Officer owns now total 1,059,153.

Among the insiders who sold shares, Bizily Scott disposed of 6,244 shares on Feb 08 at a per-share price of $27.50. This resulted in the Chief Legal Officer holding 1,737 shares of FDMT after the transaction. In another insider transaction, Kim Robert Young sold 24,552 shares at $30.05 per share on Feb 05. Company shares held by the Chief Medical Officer now total 1,043.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for FDMT in the last 3 months, the mean price target is $49.56 with high estimates of $82.00 and low estimates of $29.00. In terms of 52-week highs and lows, FDMT has a high of $35.61 and a low of $9.44.

As of this writing, FDMT has an earnings estimate of -$0.74 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.39 per share and a lower estimate of -$0.87. The company reported an EPS of -$0.77 in the last quarter, which was 4.90% higher than expectations of -$0.81.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. FDMT’s latest balance sheet shows that the firm has $247.78M in Cash & Short Term Investments as of fiscal 2021. There were $16.45M in debt and $16.34M in liabilities at the time. Its Book Value Per Share was $7.72, while its Total Shareholder’s Equity was $319.11M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FDMT is Buy with a score of 4.89.

Most Popular

Related Posts